Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 4, 2008, Pages 980-988

  Al Mamgani, Abrahim ^a   van Putten, Wim L J ^a   Heemsbergen, Wilma D ^b   van Leenders, Geert J L H ^a   Slot, Annerie ^c   Dielwart, Michel F H ^d   Incrocci, Luca ^a   Lebesque, Joos V ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Radiotherapeutic Institute Friesland   (Netherlands)

^d Zeeuws Radiotherapeutic Institute   (Netherlands)

Author keywords

Conformal; Dose escalation; External beam radiotherapy; Prostate cancer; Randomized trial; Rectal toxicity

Indexed keywords

ONCOLOGY; PATIENT MONITORING; RADIATION; RADIOLOGY; RADIOTHERAPY; TUMORS;

CONFORMAL; DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; PROSTATE CANCER; RANDOMIZED TRIAL; RECTAL TOXICITY;

TOXICITY;

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

AGED; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; PREVALENCE; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RISK ASSESSMENT; RISK FACTORS;

EID: 54049148613     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.073     Document Type: Article

References (31)

1. Perez C.A., Hanks G.E., Leibel S.A., et al. Localized carcinoma of the prostate (stages T1b, T1c, T2, and T3). Int J Radiat Oncol Biol Phys 72 (1993) 3156-3173
2. Hanks G.E. Optimizing the radiation treatment and outcome of prostate cancer. Int J Radiat Oncol Biol Phys 11 (1985) 1235-1245
3. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. B J Cancer 92 (2005) 488-498
4. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
5. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
6. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
7. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32 (1995) 3-12
8. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
9. Horwitz E.M., Thames H.D., Kuban D.A., et al. Definition of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173 (2005) 797-802
10. Vicini F.A., Kestin L.L., and Martinez A.A. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 88 (2000) 2305-2318
11. Kestin L.L., Vicini F.A., Martinez A.A., et al. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 53 (2002) 304-315
12. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
13. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
14. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
15. Chism D.B., Hanlon A.L., Horwitz E.M., et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 380-385
16. Bos L.J., Damen E.M.F., de Boer R.W., et al. Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation. Int J Radiat Oncol Biol Phys 52 (2002) 254-265
17. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
18. Cox J., Grignon D., Kaplan R., et al. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
19. Gretzer M.B., Trock B.J., Han M., et al. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiology and Oncology criteria. J Urol 168 (2002) 1419-1422
20. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
21. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 6 (2007) 459-460
22. Buyyounouski M.K., Hanlon A.L., Pollack A., et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1455-1462
23. Morgan P.B., Hanlon A.L., Horwitz E.M., et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1074-1081
24. Kuban D.A., El Mahdi A.M., and Schellhammer P.F. Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 75 (1995) 2373-2382
25. Yorke E.D., Fuks Z., Norton L., et al. Modeling the development of metastases from primary and locally recurrent tumors: Comparison with clinical data base for prostate cancer. Cancer Res 53 (1993) 2987-2993
26. Valicenti R., Lu J., Pilepich M., et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 18 (2000) 2740-2746
27. van Tol-Geerdink J.J., Stalmeier P.F., Pasker-de Jong P.C., et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 64 (2006) 5343-5345
28. Albersten P.C., Hanley J.A., and Murphy-Setzko M. Statistical considerations when assessing outcomes following treatment for prostate cancer. J Urol 162 (1999) 439-444
29. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
30. Gardner B.G., Zietman A.L., Shipley W.U., et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167 (2002) 123-126
31. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138